参芪口服液联合重组人血管内皮抑制素注射对骨肉瘤化疗患者免疫功能及临床疗效的影响  

Influence of Shenqi Oral Liquid combined with recombinant human vascular endostatin injection on immune function and clinical efficacy in patients with osteosarcoma undergoing chemotherapy

作　　者：路广秀[1] 石立峰 齐田力 张芳[1] LU Guangxiu;SHI Lifeng;QI Tianli;ZHANG Fang(The Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,Inner Mongolia,China)

机构地区：[1]内蒙古医科大学附属医院,内蒙古呼和浩特010050

出　　处：《现代中西医结合杂志》2018年第30期3324-3327,共4页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的观察参芪口服液联合重组人血管内皮抑制素注射对骨肉瘤化疗患者免疫功能及临床疗效的影响。方法将76例骨肉瘤患者随机分为观察组和对照组各38例。对照组给予化疗联合重组人血管内皮抑制素治疗,观察组在对照组治疗基础上加服参芪口服液,共治疗4周。比较2组生存质量、细胞免疫及免疫球蛋白指标的改善状况,并评估疗效。结果 2组治疗后躯体功能、认知功能、角色功能、社会功能及情绪功能评分均明显升高(P均<0. 05),且观察组治疗后各项评分均明显高于对照组(P均<0. 05);观察组治疗后CD3+、CD4+、CD4+/CD8+、NK、Ig M、Ig A及Ig G含量均明显高于对照组(P均<0. 05),CD8+水平明显低于对照组(P <0. 05);观察组治疗后总有效率明显高于对照组(P <0. 05)。结论参芪口服液联合重组人血管内皮抑制素注射液治疗能够显著改善骨肉瘤化疗患者的免疫功能,提高患者生存质量,疗效确切,值得临床加以推广。Objective It is to observe the influence of Shenqi Oral Liquid combined with recombinant human endostatin injection on immune function and clinical efficacy in patients with osteosarcoma undergoing chemotherapy.Methods Seventy-six patients with osteosarcoma were randomly divided into the observation group and the control group, 38 cases in each group. The control group was treated with chemotherapy combined with recombinant human endostatin injection; The observation group was treated with Shenqi Oral Liquid based on the control group. The 2 groups were treated for 3 months. The improvement of quality of life, cellular immunity and immunoglobulin were compared between the two groups, and the curative effect was evaluated.Results After treatment, the scores of somatic function, cognitive function, role function, social function and emotional function were significantly higher in the both groups （all P 〈0.05）, and the scores of the observation group after treatment were significantly higher than those of the control group （all P 〈0.05）. After treatment, the levels of CD3 ＋, CD4 ＋, CD4 ＋/CD8 ＋, NK, IgM, IgA and IgG in the observation group were significantly higher and the levels of CD8 ＋ was significantly lower than those in the control group （all P 〈0.05）. The total effective rate of the observation group after treatment was significantly higher than that of the control group （ P 〈0.05）.Conclusion Shenqi Oral Liquid combined with recombinant human endostatin injection can significantly improve the immune function and ameliorate quality of life in patients with osteosarcoma undergoing chemotherapy, with obvious curative effect. It is worthy to clinical promotion.

关 键 词：骨肉瘤 化疗 参芪口服液 重组人血管内皮抑制素 免疫功能 

分 类 号：R738.1[医药卫生—肿瘤]